Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 5/9/2018
SIETES contiene 92557 citas

 
 
 1 a 10 de 10 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, García-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM, CAMELLIA–TIMI 61 Steering Committee and Investigators. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med 2018:26 de agosto. [Ref.ID 102827]
2. Cita con resumen
Thapar N, Sanderson IR. Diarrhoea in children: an interface between developing and developed countries. Lancet 2004;363:641-53. [Ref.ID 69191]
3. Cita con resumen
Anónimo. GSK sees strong first year. Scrip 2002;2722:8-9. [Ref.ID 61108]
4. Cita con resumen
Anónimo. GlaxoSmithKline keen to step up R&D. Scrip 2001;2690:9. [Ref.ID 59410]
5.Tiene citas relacionadas
Mangel AW. Alosetron in irritable bowel syndrome. Author's reply. Lancet 2000;356:164-5. [Ref.ID 51748]
6.Tiene citas relacionadas
McColl KEL. Alosetron in irritable bowel syndrome. Lancet 2000;356:164. [Ref.ID 51747]
7.
Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet 1999;37:399-431. [Ref.ID 47933]
8.
Stokes GS. Serotonin receptor agonists and antagonists - Clinical application. i. Cardiovascular. Australian Prescriber 1991;14:49-50. [Ref.ID 16450]
9.
Persson B, Heykants J, Hedner T. Clinical pharmacokinetics of ketanserin. Clin Pharmacokinet 1991;20:263-79. [Ref.ID 16245]
Seleccionar todas
 
 1 a 10 de 10